Skip to main content
. 2024 Jul 22;15:1413250. doi: 10.3389/fmicb.2024.1413250

Table 2.

Clinical trial data and safety profile of the live attenuated IXCHIQ vaccine.

Study Participants Vaccine recipients Placebo recipients Seroresponse rate (28 days postvaccination) Seroresponse rate (6 months postvaccination)
1 3,500 2,500 1,000 98.9% 96.3%
2 3,500 2,500 1,000 98.9% 96.3%